SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
| Status: | Recruiting |
|---|---|
| Conditions: | HIV / AIDS, Endocrine, Gastrointestinal |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | August 2006 |
| Contact: | Richard A. Elion, MD |
| Email: | drrelion@aol.com |
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24
weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA
<50 copies/mL at entry
weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA
<50 copies/mL at entry
Inclusion Criteria:
- Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir
(Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
- Viral load <50 copies/ml
Exclusion Criteria:
- Viral load >50 copies/ml
- Having taken more than one antiretroviral regimen
We found this trial at
1
site
Click here to add this to my saved trials
